Início › Câncer Endometrial › Alabama
Ensaios clínicos de Câncer Endometrial em Alabama
19 estudos para Câncer Endometrial estão buscando participantes em locais em Alabama.
Cidades em Alabama
Texto oficial do estudo (Inglês)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- University of Alabama at Birmingham Cancer Center, Birmingham
- University of South Alabama Mitchell Cancer Institute, Mobile
RecrutandoFase 2
Todas as idades · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05564377A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)
- GSK Investigational Site, Birmingham
RecrutandoFase 3
Idades 18 e acima · Mulheres · Atualizado em 2 de out. de 2026 · NCT07286331Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- University of Alabama at Birmingham Cancer Center, Birmingham
RecrutandoFase 3
Idades 18 e acima · Mulheres · Atualizado em 2 de out. de 2026 · NCT07198074A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital, Birmingham
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT06760819177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- Dothan Hematology & Oncology, Dothan
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT07189871Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- University of Alabama at Birmingham Cancer Center, Birmingham
RecrutandoFase 2
Idades 18 e acima · Mulheres · Atualizado em 28 de set. de 2026 · NCT05112601DESTINY-PANTUMOUR04
- Research Site, Birmingham
RecrutandoEstudo observacional
Idades de 18 a 130 · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT07124000Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- University of Alabama_6th Ave, Birmingham
RecrutandoFase 1/2
Idades 18 e acima · Mulheres · Atualizado em 25 de set. de 2026 · NCT03564340A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- University of South Alabama, Mitchell Cancer Institute ( Site 6033), Mobile
RecrutandoFase 3
Idades 18 e acima · Mulheres · Atualizado em 17 de set. de 2026 · NCT06952504ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- University of Alabama at Birmingham, Birmingham
RecrutandoEstudo observacional
Idades 18 e acima · Todos os sexos · Atualizado em 14 de set. de 2026 · NCT05059444Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- University of Alabama Birmingham, Birmingham
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 10 de set. de 2026 · NCT06293898Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
- USAH Mitchell Cancer Inst, Mobile
RecrutandoFase 3
Idades 18 e acima · Mulheres · Atualizado em 9 de set. de 2026 · NCT07166094Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Children's Hospital of Alabama, Birmingham
RecrutandoFase 1/2
12 Months – 30 Years · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT04851119A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- University of Alabama at Birmingham, Birmingham
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 30 de jul. de 2026 · NCT04657068The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in Tampons
- University of Alabama at Birmingham, Birmingham
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Idades de 18 a 99 · Mulheres · Atualizado em 29 de jul. de 2026 · NCT03538665A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- University of Alabama at Birmingham, Birmingham
- University of Alabama at Birmingham, IDS Pharmacy, Birmingham
- University of Alabama at Birmingham, Birmingham
- e mais 1
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 22 de jul. de 2026 · NCT05208762Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
- 004, Birmingham
RecrutandoFase 2
Idades 18 e acima · Mulheres · Atualizado em 16 de jul. de 2026 · NCT06906341Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
- O'Neal Comprehensive Cancer Center at UAB, Birmingham
RecrutandoFase 1/2
Idades 18 e acima · Mulheres · Atualizado em 15 de abr. de 2026 · NCT05559879SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Birmingham
- Massive Bio SYNERGY-AI site, Mobile
RecrutandoEstudo observacional
Todas as idades · Todos os sexos · Atualizado em 28 de out. de 2025 · NCT03452774Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.